home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Aurora And Twilight For Tumors

  March, 2 2004 10:13
your information resource in human molecular genetics
Targeted approaches to cancer treatment are showing increasing signs of success as alternatives to traditional chemotherapy. In the March issue of Nature Medicine, Karen Miller and colleagues use one such drug, called VX-680, to suppress tumor growth.

VX-680 inhibits the enzymatic activity of Aurora kinases, proteins that have an important role in cell division. Because cancer cells divide rapidly, blocking Aurora kinases selectively targets those cells. The authors show that, in a mouse model of cancer, VX-680 inhibits the proliferation of cancer cells, resulting in slower tumor growth.

If further studies confirm the results, VX-680 might be used to specifically target tumor cells and minimize the side effects and toxicity seen with other cancer therapies, the authors suggest.

Author contact:

Karen M. Miller
Vertex Pharmaceuticals (Europe) Ltd.
Abingdon, UK
Tel: +44 1235 438810
E-mail: karen_miller@vrtx.com

Also available online.

(C) Nature Medicine press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.